MLYS MINERALYS THERAPEUTICS INC

Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023

Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023

RADNOR, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton and Chief Financial Officer and Chief Business Officer Adam Levy will participate in a fireside chat at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 5 p.m. PT

The live webcast of the fireside chat can be accessed under “” on the Investor Relations section of the Mineralys website at . A replay of the webcast will be available on the Company’s website for approximately 90 days.

Bank of America Securities 2023 Health Care Conference:

Date:Wednesday, May 10, 2023
Time:5:00 p.m. PT  



About Mineralys

Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension.

Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit . Follow Mineralys on .

Contact:

Investor Relations

Media Relations

Tom Weible

Elixir Health Public Relations

Phone: (1) 515-707-9678

Email:



EN
27/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINERALYS THERAPEUTICS INC

 PRESS RELEASE

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrosta...

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results – The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with hypertension – – Topline results from the Phase 2 Explore-OSA exploratory trial did not reduce AHI; demonstrated a clinically meaningful reduction in blood pressure and favorable safety and tolerability in this population with d...

 PRESS RELEASE

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 F...

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2025, after the fina...

 PRESS RELEASE

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing ...

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 23, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 27,920 shares and...

 PRESS RELEASE

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing ...

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering 33,504 shares and in...

 PRESS RELEASE

Mineralys Therapeutics Provides Corporate Update and Announces Partici...

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones. In...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch